Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)

Inclusion Criteria: * BCVA of ≥ 24 and ≤ 73 letters (20/40 or worse but at least 20/320) by an ETDRS chart. BCVA of the non-study eye must be no worse than 20/400 Snellen equivalent) * Diagnosis of diabetes mellitus, type 1 or 2 with non-proliferative or non-high risk proliferative diabetic retinopathy. Any one of the following will be considered sufficient evidence that diabetes is present: * Current regular use of insulin for the treatment of diabetes * Current regular use of oral hypoglycemic agents for the treatment of diabetes * DME based on investigator's clinical evaluation and demonstrated on fundus photographs, fluorescein angiograms, and/or spectral domain-optical coherence tomography (SD-OCT) * Mean foveal thickness of at least 325 µm by SD-OCT * Ability and willingness to comply with the treatment and follow up procedures * Ability to understand and sign the informed consent form * Intraocular pressure of ≤ 21 mm Hg on 2 or fewer IOP lowering medications Exclusion Criteria: * Pregnant patients, currently lactating patients, or females of childbearing potential (unless using reliable contraception such as double barrier, surgical sterilization, oral contraceptives, intrauterine device (IUD), etc. * Body weight less than 55 kg * Allergy or hypersensitivity (known or suspected) to fluorescein or any component of the investigational product or delivery system * Any ocular surgery in the study eye within 12 weeks of screening * History of vitrectomy in the study eye…